论文部分内容阅读
目的观察依达拉奉治疗急性脑梗死的临床疗效。方法将108例急性脑梗死患者随机分为治疗组和对照组,对照组应用抗血小板降纤等常规治疗,治疗组在常规治疗的基础上加用依达拉奉注射液30 mg加生理盐水100 m l静脉滴注,2次/d,连用14 d。两组病例于治疗前后分别进行神经功能缺损量表评定(CSS中国卒中量表)。结果两组治疗后CSS均有所改善,治疗组神经功能改善程度及有效率优于对照组(P<0.05),治疗组无明显不良反应。结论依达拉奉作为脑保护剂治疗急性脑梗死,可明显促进脑梗死患者的神经功能恢复,疗效确切,安全可靠。
Objective To observe the clinical efficacy of edaravone in the treatment of acute cerebral infarction. Methods One hundred and eighty patients with acute cerebral infarction were randomly divided into treatment group and control group. The control group was given conventional antiplatelet therapy such as antifibrinolytic therapy. The treatment group was treated with edaravone 30 mg and saline 100 ml intravenous infusion, 2 times / d, once every 14 d. Two groups of patients before and after treatment were assessed neurological deficit scale (CSS China Stroke Scale). Results After treatment, CSS improved in both groups. The degree of neurological improvement and effective rate in the treatment group were better than those in the control group (P <0.05). There was no significant adverse reaction in the treatment group. Conclusion Edaravone as a brain protectant in the treatment of acute cerebral infarction can significantly promote the recovery of neurological function in patients with cerebral infarction. The curative effect is safe and reliable.